These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15640652)

  • 1. Afelimomab-another therapeutic option in sepsis therapy?
    Grass G; Neugebauer EA
    Crit Care Med; 2004 Nov; 32(11):2343-4. PubMed ID: 15640652
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.
    Rondon E; Venkataraman R
    Crit Care; 2005 Aug; 9(5):E20. PubMed ID: 16277704
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
    Reinhart K; Menges T; Gardlund B; Harm Zwaveling J; Smithes M; Vincent JL; Tellado JM; Salgado-Remigio A; Zimlichman R; Withington S; Tschaikowsky K; Brase R; Damas P; Kupper H; Kempeni J; Eiselstein J; Kaul M
    Crit Care Med; 2001 Apr; 29(4):765-9. PubMed ID: 11373466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths.
    Salluh JI; Póvoa P
    Crit Care Med; 2010 Aug; 38(8):1749-51. PubMed ID: 20647805
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving survival for sepsis: on the cutting edge.
    Rello J; Rodriguez A
    Crit Care Med; 2003 Dec; 31(12):2807-8. PubMed ID: 14668621
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis.
    Ayala A; Knotts JB; Ertèl W; Perrin MM; Morrison MH; Chaudry IH
    Arch Surg; 1993 Jan; 128(1):89-94; discussion 94-5. PubMed ID: 8418786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magic bullets and surrogate biomarkers circa 2009.
    Delano MJ; Moldawer LL
    Crit Care Med; 2009 May; 37(5):1796-8. PubMed ID: 19373047
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal antibody effective against septicemia.
    Oncology (Williston Park); 1990 Nov; 4(11):74. PubMed ID: 2150328
    [No Abstract]   [Full Text] [Related]  

  • 11. [Critical care research].
    Perner A; Heslet L; Larsson A; Toft P; Tønnesen EK
    Ugeskr Laeger; 2007 Feb; 169(8):677-9. PubMed ID: 17313911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surviving Sepsis Guidelines: A Continuous Move Toward Better Care of Patients With Sepsis.
    De Backer D; Dorman T
    JAMA; 2017 Feb; 317(8):807-808. PubMed ID: 28114630
    [No Abstract]   [Full Text] [Related]  

  • 13. Daily monitoring of biomarkers of sepsis in complicated long-term ICU-patients: can it support treatment decisions?
    Iapichino G; Marzorati S; Umbrello M; Baccalini R; Barassi A; Cainarca M; Colombo Pavini F; Mantovani E; Mauri A; Moroni B; Noto A; Melzi D'Eril GV; Langer M
    Minerva Anestesiol; 2010 Oct; 76(10):814-23. PubMed ID: 20935617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Search for effective immunomodulating strategies against sepsis.
    Vincent JL
    Lancet; 1998 Mar; 351(9107):922-3. PubMed ID: 9734931
    [No Abstract]   [Full Text] [Related]  

  • 15. Reducing mortality in severe sepsis: the Surviving Sepsis Campaign.
    Townsend SR; Schorr C; Levy MM; Dellinger RP
    Clin Chest Med; 2008 Dec; 29(4):721-33, x. PubMed ID: 18954706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Interleukin-6 a better predictor of successful antibiotic therapy than procalcitonin and C-reactive protein? A single center study in critically ill adults.
    Weidhase L; Wellhöfer D; Schulze G; Kaiser T; Drogies T; Wurst U; Petros S
    BMC Infect Dis; 2019 Feb; 19(1):150. PubMed ID: 30760225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. It takes an intensivist.
    Silverman LZ; Hoesel LM; Desai A; Posa P; Purtill MA; Brandt MM
    Am J Surg; 2011 Mar; 201(3):320-3; discussion 323. PubMed ID: 21367371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C: beyond 28 days.
    Manocha S; Walley KR
    Crit Care Med; 2004 Nov; 32(11):2348-9. PubMed ID: 15640656
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous physiologic monitoring and the identification of sepsis: what is the evidence supporting current clinical practice?
    Giuliano KK
    AACN Adv Crit Care; 2006; 17(2):215-23. PubMed ID: 16767023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.